Cardinal Health Inc. (CAH)
Cardinal Health (CAH) Laps the Stock Market: Here's Why
Cardinal Health (CAH) closed at $253.71 in the latest trading session, marking a +2.41% move from the prior day.
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge
As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.
Here's Why Cardinal Health (CAH) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
Here is how Cardinal Health (CAH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now
CAH enters fiscal 2027 with Pharma profit growth, emerging growth engines and efficiency gains offsetting revenue headwinds.
Cardinal Health (CAH) Outperforms Broader Market: What You Need to Know
Cardinal Health (CAH) closed the most recent trading day at $233.12, moving +2.11% from the previous trading session.
Cardinal Health: I'm Still Buying After Checking The Numbers
Cardinal Health remains a Buy, driven by robust FY2026 results, strong cash flow, and credible FY2027 guidance. CAH delivered 14% revenue growth, 20% gross margin expansion, and doubled free cash flow, despite ongoing thin margins and higher current liabilities. FY2027 guidance targets 13-15% non-GAAP EPS growth, with profit improvement expected from both Pharmaceutical and Specialty Solutions and higher-margin 'Other' segments.
Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds
Cardinal Health NYSE: CAH CEO Jason Hollar said the company expects fiscal 2027 to extend the broad operating momentum it generated in fiscal 2026, with all five operating segments positioned for what he described as a “constructive” period.
Cardinal Health Sees Growth Normalize as Specialty, At-Home Investments Expand
Cardinal Health NYSE: CAH CEO Jason Hollar said the company's fiscal 2026 performance was supported by double-digit earnings growth across each of its five operating segments, while fiscal 2027 guidance reflects continued growth from a more normalized base.
Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?
Cardinal Health expects IRA pricing changes to pressure Pharma revenues while protecting profitability through compensation and durable distribution agreements.
Cardinal Health (CAH) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Cardinal Health (CAH) settling at $232.36, representing a -1.08% change from its previous close.
